Real-world single-center experience with direct-acting antivirals for improvement of the liver fibrosis after chronic hepatitis C treatment

Sun Hee Lee, Hyun Phil Shin and Joung Il Lee

Abstract

Background: Recently, new direct-acting antivirals (DAAs) are known to eradicate chronic hepatitis C (CHC) virus infection and prevent the progression of liver fibrosis. Liver fibrosis may predispose to liver cirrhosis or hepatocellular carcinoma. We investigated the effect of DAAs on liver fibrosis using non-invasive methods, and evaluated the correlations of these methods.

Methods: We retrospectively analyzed 68 patients with CHC who were treated with DAAs and reached sustained virologic response at 12 weeks post-treatment from January 2016 to October 2018. The degree of liver fibrosis was assessed using serum biomarkers, such as AST-to-platelet ratio index (APRI) and fibrosis-4 (FIB-4) index. Liver stiffness was assessed using two-dimensional shear-wave elastography (2D-SWE). The pre- and post-treatment serum biomarker levels and SWE findings were evaluated and compared.

Results: A total of 68 patients with CHC were enrolled. The median age was 58 years (52.3–73 years) and 37 patients (54.4%) were female. After treatment, the median APRI was decreased from 0.701 to 0.328 (P < 0.0001), and the median FIB-4 was decreased from 2.355 to 1.860 (P < 0.0001). The median kPa in 2D-SWE significantly reduced from 6.85 to 5.66 (P = 0.013). APRI and FIB-4 were significantly correlated pre- and post-treatment; however, the correlation between the serum biomarkers and 2D-SWE was partially significant.

Conclusion: The serum fibrosis biomarkers and liver stiffness on 2D-SWE were shown to be improved after the treatment with DAAs. Further research including larger number of patients is needed to compare the efficacy of each evaluating method.

Keywords

Direct-acting antivirals, chronic hepatitis C, liver fibrosis

Date received: 13 January 2020; accepted: 28 October 2020

Introduction

The global prevalence of Hepatitis C virus (HCV) infection was estimated at 1.0% and the number of patients was estimated at 71 million in 2015. Chronic HCV infection is known to be the leading cause of liver cirrhosis, hepatocellular carcinoma (HCC), and liver-related mortality. The treatment of chronic HCV infection has been changed rapidly due to the new direct-acting antivirals (DAAs), which have superior efficacy in all genotypes and less adverse effects than the previous interferon (INF)-based treatment. The sustained virologic response at 12 weeks post-treatment (SVR12) is defined as the absence of HCV RNA after 12 weeks of antiviral treatment. Within the current decade, HCV can be eliminated in most patients with chronic HCV using DAAs, as assessed by the SVR12. Its eradication reduces the incidence...
of cirrhosis and HCC, but these cannot be completely prevented in patients with advanced liver fibrosis.6,7 The degree and extent of liver fibrosis is the predictor of disease progression and is related to the need and duration of the antiviral treatment, as well as the choice of treatment regimen.8–10 The SVR after interferon treatment improves the liver fibrosis and reduces all-cause mortality in patients with chronic HCV.11,12 Therefore, the liver fibrosis status in patients cured by DAA is important for surveillance and management. It has been suggested that liver fibrosis can be partially reversed after DAA therapy. This was confirmed by diminishment of the liver stiffness in transient elastography (TE) after treatment13 and is probably due to the reduced inflammation and regression of the fibrosis.14

The gold standard of measuring liver fibrosis is liver biopsy, but this test is known to have several disadvantages,15–17 such as invasiveness, inter-observer variability at pathologic evaluation, inadequate sampling size, and sampling variations. In addition, the dynamic process of liver fibrosis cannot be evaluated by biopsy.18 Therefore, various non-invasive methods for evaluating liver fibrosis have been used. Non-invasive scoring systems based on laboratory blood tests, such as AST-to-platelet ratio index (APRI) and fibrosis-4 (FIB-4) score are widely used because they are easy to use in clinical practice and are easily reproducible [16]. In recent years, multiple studies have used TE to evaluate the liver fibrosis.18 Both serum biomarkers and TE have shown equivalent performance to evaluate the liver fibrosis, but TE was superior in detecting cirrhosis.19,20 Shear wave elastography (SWE) can be performed as an additional test during liver ultrasonography and does not require the purchase of additional machines like TE; however, its reproducibility has not been confirmed.21

Even though it is of great importance to predict the progression of hepatitis C-related liver disease, real-world data evaluating fibrosis change after DAA treatment are limited. In the present study, we assessed the change in liver fibrosis after HCV treatment using various non-invasive measurements and evaluated the correlations of each method. We compared the change in the APRI, FIB-4, and liver stiffness value of SWE after DAA treatment.

Methods

We retrospectively analyzed 68 patients with chronic hepatitis C (CHC) who underwent DAA treatment from January 2016 to October 2018 at the Kyung Hee University Hospital, Gangdong, Seoul, Korea. HCV genotyping was performed in all patients. All patients underwent routine follow-ups at the outpatient clinic during the treatment, and none had failed to complete the treatment because of adverse events. Complete blood count, liver functional tests, and HCV RNA were evaluated before and 12 weeks after the end of treatment. The degree of liver fibrosis was assessed using the APRI and FIB-4, which were calculated using serum indirect markers. The APRI was calculated as AST level (IU/L)/Upper limit of norma ASTl (IU/L)/platelet count (10⁹/L) × 100, and the FIB-4 index was calculated as age (years) × AST (IU/L)/platelet count (10⁹/L) × ALT²/ (IU/L).22 In this study, the lowest and highest cutoff values of advanced fibrosis were set as APRI scores of 1 and 2, respectively.23 For FIB-4, the lowest and highest cutoff values of advanced fibrosis were defined as FIB-4 scores of 1.45 and 3.25, respectively.24,25 Liver stiffness was assessed using two-dimensional shear-wave elastography (2D-SWE). The values were expressed in kilopascals (kPa) and were related to the validated MEAVIR fibrosis stages with the following cut-off values: ≤5.48 kPa = F0, 5.48–8.29 kPa = F1, 8.29–9.40 kPa = F2, 9.40–11.9 kPa = F3, and ≥11.9 kPa = F4. SWE was performed by three abdominal radiologists using a C1-6 curved array probe of LOGIQ E9 (GE Healthcare, Chicago, IL, USA). Because this study was a retrospective analysis of the existing administrative and clinical data, informed consent was not required. This study was approved by the Institutional Review Board of the Kyung Hee University Hospital at Gangdong.

Statistical analysis

Statistical significance was defined as P < 0.05 and continuous variables were expressed as the medians (interquartile range or proportions). None of the variables satisfied the normality assumption as confirmed by the Shapiro-Wilk normality test. The Wilcoxon signed rank test was used to analyze the differences among continuous variables at pre-treatment and post-treatment, and the McNemar-Bowker test was used to determine the differences in the dichotomous dependent variables between the paired groups. The relationships between the variables were assessed using the Spearman’s correlation coefficients, which are often expressed as Rho. If the Rho value was 0, there was no correlation between the comparison groups, and the closer to 1, the stronger the correlation. All statistical analyses were performed with SPSS software version 24.0 (SPSS Inc., Chicago, IL, USA) and R version 3.5.1 (The R Foundation for Statistical Computing, Vienna, Austria).
Results

Patients

The baseline characteristics are shown in Table 1. The median age of the 68 patients was 58 (interquartile range, 52.3–73.0) years and 31 patients (45.6%) were male (Table 1). Eleven patients (16.2%) had consumed significant amounts of alcohol, and 14 patients (20.6%) were smokers. Twenty-one patients (30.9%) had hypertension and 12 (17.6%) had diabetes mellitus. None of the patients had a co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV), or a history of hepatocellular carcinoma. There were none post-liver transplant patients. Eighteen patients (26.4%) had compensated cirrhosis, and none had Child Pugh score C. Eight patients (11.8%) had received previous HCV treatment by pegylated interferon or interferon and ribavirin. Among the 48 patients with genotype 1b, 29 received asunaprevir plus daclatasvir for 24 weeks, 15 received elbasvir plus grazoprevir for 12 weeks, 3 received ombitasvir plus paritaprevir plus ritonavir and dasabuvir for 12 weeks, and one received ledipasvir plus sofosbuvir for 12 weeks. All 18 patients with genotype 2a received sofosbuvir plus ribavirin, 14 of whom were treated for 12 weeks and 4 for 16 weeks. One patient with genotype 1a received ledipasvir plus sofosbuvir for 12 weeks and one patient with genotype 3 received daclatasvir plus sofosbuvir for 12 weeks.

Changes of test results after DAA treatment

The laboratory test and SWE results of the patients before and after the HCV treatment are shown in Table 2. Platelet (PLT), Hemoglobin (Hb), and TB (total bilirubin) levels did not show any significant difference pre- and post-treatment. The levels of serum HCV RNA, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) significantly decreased after the HCV treatment. In detail, the serum median levels of AST had decreased from 53.5 (34.8–73.3) IU/L to 23.6 (18.0–29.3) IU/L after treatment, and the serum median levels of ALT had decreased from 52.5 (34.8–82.5) IU/L to 16 (11.0–22.3) IU/L. The median value of HCV RNA before treatment was 1910000 (396000–3600000) log10IU/mL and the HCV RNA measured after treatment was all negative. After the HCV treatment, the APRI was decreased from 0.701 (0.391–1.705) to 0.328 (0.208–0.497, P < 0.0001), and FIB-4 was decreased from 2.335 (1.436–5.095) to 1.860 (1.267–3.391, P < 0.0001). The distribution of calculated fibrosis was determined by the lowest and highest cutoff values of the APRI and FIB-4 and was classified to three groups. According to the APRI

Table 1. Baseline patient characteristics.

| Characteristics                  | Total (N = 68) |
|----------------------------------|---------------|
| Age (year)a                      | 58 (52.3–73)  |
| Female sex (n, %)                | 37 (54.4%)    |
| Alcohol ≥40 g/day (n, %)         | 11 (16.2%)    |
| Smoker (n, %)                    | 14 (20.6%)    |
| Hypertension (n, %)              | 21 (30.9%)    |
| Diabetes (n, %)                  | 12 (17.6%)    |
| Cirrhosis (n, %)                 | 18 (26.4%)    |
| Treatment experiencedb (n, %)    | 8 (11.8%)     |
| HCV genotype and treatment regimen (n, %) |           |
| lb                               | 48 (70.6%)    |
| la                               | 1 (1.5%)      |
| 2                                | 18 (26.4%)    |
| 3                                | 1 (1.5%)      |

aAge is expressed as median with interquartile range.
bHistory of treatment with peginterferon or interferon, with ribavirin.

Table 2. Laboratory and elastography results before and after HCV treatment.

|                      | Pre-treatment | Post-treatment | p-value |
|----------------------|---------------|----------------|---------|
| HCV RNA (log10IU/mL) | 1910000 (396000–3600000) | 0 (–)          | <0.0001 |
| PLT (×10^5/mm^3)     | 180.5 (128.5–225.3) | 180.0 (130.5–239.0) | 0.063   |
| Hb (g/dL)            | 14.1 (12.8–14.8)   | 13.8 (12.9–14.9)  | 0.261   |
| Alb (g/dL)           | 4.2 (3.9–4.4)      | 4.3 (3.9–4.5)    | 0.014   |
| AST (IU/L)           | 53.5 (34.8–73.3)   | 23.6 (18.0–29.3)  | <0.0001 |
| ALT (IU/L)           | 52.5 (34.8–82.5)   | 16 (11.0–22.3)   | <0.0001 |
| TB (mg/dL)           | 0.9 (0.6–1.1)      | 0.7 (0.5–1.0)    | 0.525   |
| APRI                 | 0.701 (0.391–1.705)| 0.328 (0.208–0.497) | <0.0001 |
| FIB-4                | 2.335 (1.436–5.095)| 1.860 (1.267–3.391) | <0.0001 |
| SWE (n = 27)a        | 6.85 (5.63–11.45)  | 5.66 (4.83–7.43)  | 0.013   |

HCV: hepatitis C virus; PLT: platelet; Hb: hemoglobin; Alb: albumin; AST: aspartate aminotransferase; ALT: alanine aminotransferase; TB: total bilirubin; APRI: aspartate aminotransferase/platelet ratio index; FIB-4: fibrosis-4; SWE: shear–wave elastography.
aTwenty–seven patients underwent SWE before and after treatment. All values are expressed as median with interquartile range. p < 0.05 was considered significant.
Changes of fibrosis using APRI and FIB-4 scores after HCV treatment.

|      | Post-treatment APRI score |      |      |
|------|---------------------------|------|------|
|      | <1.0                      | 1.0–2.0 | >2.0   |
| Pre-treatment APRI score | 43  | 0    | 0    |
| 1.0–2.0 | 11  | 1    | 0    |
| >2.0  | 10  | 1    | 2    |

p < 0.001

|      | Post-treatment FIB-4 score |      |      |
|------|---------------------------|------|------|
|      | <1.45                     | 1.45–3.25 | >3.25 |
| Pre-treatment FIB-4 score | 17  | 1    | 0    |
| 1.45–3.25 | 6   | 20   | 0    |
| >3.25  | 1   | 5    | 18   |

p = 0.023

A. Patients were divided into three groups according to the APRI cut-off value. B. Patients were divided into three groups according to the FIB-4 cut-off value. McNemar–Bowker test. P < 0.05 was considered significant.

Discussion

CHC infection causes liver fibrosis, resulting in decompensated cirrhosis and liver cancer, leading to liver-related death.26 Antiviral therapies can decrease the incidence rate of hepatocellular carcinoma,27 but not completely eliminate the risk, even in patients who achieved SVR. The patients with an advanced fibrosis had a higher risk of HCC, and HCC surveillance using liver ultrasound with or without alpha-fetoprotein test twice per year are recommended for patients with an advanced fibrosis.28

Previous studies have shown that the liver fibrosis was improved in patients who underwent interferon (IFN)-based HCV treatment.11 The IFN therapy seemed to inhibit the hepatic hemostasis and profibrotic cytokines, such as bFGF and TGF-β1, resulting in anti-inflammatory and antifibrotic effects.29 Many studies have shown that patients with CHC who achieved SVR after the treatment with DAAs had improvement in terms of liver stiffness.30,31 However, the real-world data using various methods to evaluate the change of fibrosis has not been well studied.

Repeated liver biopsy, before and after treatment, is practically difficult; therefore, non-invasive methods for liver fibrosis evaluation have been used. The non-invasive serum biomarkers and elastography are easy to use and elastography is superior in detecting cirrhosis [19,20]. The liver stiffness is influenced by the liver fibrosis; however, it is also influenced by the necro-inflammatory activity in the liver.32 Therefore, the improvement of the liver stiffness reflects the improvement of both the liver fibrosis and the necroinflammation of the liver. As a result, it is difficult to accurately quantify the improvement in the liver fibrosis using the SWE or TE methods for measuring the liver stiffness. Factors such as the flare of transaminases, cholestasis, non-fasting, and liver steatosis are further limitations for accurately assessing the liver fibrosis.33 Additionally, there has been little analysis on how the improvement after DAA treatment could be properly assessed and on the correlation between the methods used to evaluate the fibrosis.

In our study, the overall fibrosis-related test results were improved after DAA treatment. The APRI, FIB-4, and SWE findings showed significant improvement. The severity of the fibrosis as measured by the cutoff values of APRI and FIB-4 scores was also improved after HCV treatment (Table 3).

Only 27 patients underwent SWE before and after treatment; therefore, we assessed the correlation between the APRI, FIB-4, and SWE as indicators of liver fibrosis. The correlation between the serum biomarkers, APRI and FIB-4, was statistically significant both pre- and post-treatment.
We also evaluated the correlation between the serum biomarkers and SWE. The pre-treatment APRI and SWE (Rho = 0.58, p = 0.0009) were significantly correlated; however, the post-treatment APRI and SWE failed to show a significant correlation (Rho = 0.27, p = 0.132).

Conversely, the FIB-4 and SWE showed a statistically significant correlation both pre and post-treatment (Figure 2(d) and 2(e)).

The limitations of our study are the short duration of the follow-up and the small number of patients who had undergone SWE (27 of 68 patients) before and after treatment. Even after SVR12, fibrosis can be improved, so studies about fibrosis need to be over a long period of time. Due to the small number of patients, there was difficulty to prove the exact correlation with other marks. And it is possible that the patients with a high AST level before treatment were included more and the degree of fibrosis of serum biomarkers may be exaggerated. In addition, this was a retrospective study, and we assessed several different regimens and did not include many patients in each regimen.
In conclusion, the improvement in the noninvasive fibrosis panels and elastography seems to be evident in patients after DAA treatment and each method showed a possibility of correlation. In future studies, it is necessary to observe the long-term effect of DAAs on liver fibrosis using various methods including transient elastography and to establish proper tools that can monitor the change of liver fibrosis after DAA therapy. Furthermore, more studies are needed to further verify the effect of DAA treatment on the incidence of hepatocellular carcinoma.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Hyun Phil Shin https://orcid.org/0000-0002-9350-1079
References

1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017; 2: 161–176.

2. Westbrook RH and Dusheiko G. Natural history of hepatitis C. J Hepatol 2014; 61: S58–S68.

3. Fried MW, Shariffi MA, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982.

4. Yoshida EM, Sulikowski MS, Gane EJ, et al. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology 2015; 61: 4145.

5. Spengler U. Direct antiviral agents (DAAs) – a new age in the treatment of hepatitis C virus infection. Pharmacol Ther 2018; 183: 118–126.

6. Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013; 158: 329–337.

7. Morgan TR, Ghany MG, Kim HY, et al. Outcome of patients with hepatitis C. J Hepatol 2015; 63: 833–844.

8. Ferenci P, Kozbial K, Mandorfer M, et al. HCV targeting of patients with cirrhosis. J Hepatol 2015; 63: 1015–1022.

9. Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62: 932–954.

10. Lee HS, Kweon YO, Tak WY, et al. Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients. Clin Mol Hepatol 2013; 19: 148–155.

11. Shiratori Y, Imazeki F, Moriyma M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517–524.

12. Backus LI, Boothroyd DB, Phillips BR, et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 509–516 e501.

13. Hezode C, Castera L, Roudot-Thoraval F, et al. Liver stiffness diminishes with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther 2011; 34: 656–663.

14. Molleken C, Ahrens M, Schlosser A, et al. Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients. Clin Mol Hepatol 2019; 25: 42–51.

15. Bravo AA, Sheth SG and Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495–500.

16. Bedossa P, Dargere D, and Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449–1457.

17. Rousselet MC, Michalak S, Dupre F, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005; 41: 257–264.

18. Knop V, Hofmann WP, Buggisch P, German Hepatitis C-Registry, et al. Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatment. J Viral Hepat 2019; 26: 224–230.

19. Zarski JP, Sturm N, Guechot J, ANRS HCEP 23 Fibrostar Group, et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol 2012; 56: 55–62.

20. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343–350.

21. Barr RG, Ferraioi G, Palmeri ML, et al. Elastography assessment of liver fibrosis: Society of Radiologists in Ultrasound consensus conference statement. Radiology 2015; 276: 845–861.

22. European Association for Study of Liver and Asociacion Latinoamericana para el Estudio del Higado Collaborators. EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63: 237–264.

23. Lin ZH, Xin YN, Dong QI, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53: 726–736.

24. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32–36.

25. Cheng PN, Chiu HC, Chiu YC, et al. Of FIB-4 and transient elastography in evaluating liver fibrosis of chronic hepatitis C subjects in community. PLos One 2018; 13: e0206947.

26. Singh S, Fujii LL, Murad MH, et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and Meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 1573–1584. e1571–e1572; quiz e1588–e1579.

27. Kanwal F, Kramer J, Asch SM, et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 2017; 153: 996–1005. e1001.

28. European association for study of L. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63: 199–236.

29. Tanabe J, Izawa A, Takemi N, et al. Interferon-beta reduces the mouse liver fibrosis induced by repeated administration of concanavalin A via the direct and indirect effects. Immunology 2007; 122: 562–570.

30. Tada T, Kumada T, Toyoda H, et al. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved
31. Knop V, Hoppe D, Welzel T, et al. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. *J Viral Hepat* 2016; 23: 994–1002.

32. Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. *Hepatology* 2007; 47: 380–384.

33. Perazzo H, Veloso VG, Grinsztejn B, et al. Factors that could impact on liver fibrosis staging by transient elastography. *Int J Hepatol* 2015; 2015: 1–5.